UCSF Helen Diller Family Comprehensive Cancer Center | Strategic Alliance Partners

Latest from UCSF Helen Diller Family Comprehensive Cancer Center


Monitoring and Managing Hyperphosphatemia

February 07, 2024

Hyperphosphatemia is the most common AE associated with FGFRi treatments and can impact patient quality of life, but there are treatments and possible diet changes that may help mitigate this AE.

Patient Perspective Regarding FGFRi Adverse Event Profiles

January 31, 2024

A patient with cholangiocarcinoma shares her experience while being treated with an FGFR inhibitor, as well as insights on what providers should tell their patients to help them best manage or possibly prevent these adverse events.

Improving Prediction of Advanced Breast Cancer Among Women of Different Races and Ethnicities

December 25, 2023

Regular screenings may decrease the chance of diagnosis of advanced breast cancer in some women and lead to a 20% reduction in breast cancer mortality. However, the chances of being diagnosed with advanced breast cancer are higher among women who are Black or Hispanic/Latinx, overweight, or obese.

Dr Huppert on Sequential Treatment with T-DXd and Sacituzumab Govitecan in HER2-Low Breast Cancer

December 21, 2023

Laura A. Huppert, MD, discusses the impact of sequential treatment with fam-trastuzumab deruxtecan-nxki and sacituzumab govitecan-hziy on outcomes in patients with HER2-low metastatic breast cancer, according to findings from a retrospective analysis.

x